CS
CPRX

Candriam SCA’s Catalyst Pharmaceutical CPRX Stock Holding History

Candriam SCA’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-560,000
Closed -$1.41M – 757
2017
Q3 		$1.41M Hold
560,000
– – 0.02% 513
2017
Q2 		$1.55M Sell
560,000
-40,000
-7% -$83.5K 0.03% 507
2017
Q1 		$1.17M Buy
+600,000
New +$764K 0.02% 539

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Candriam SCA's CPRX Position: Q4 2017 in Review

Candriam SCA sold out of Catalyst Pharmaceutical (CPRX) in Q4 2017, closing a stake of 560,000 shares — an estimated $1.41M sold.

Candriam SCA first reported a position in CPRX in Q1 2017 and held it in 3 quarters. The position peaked at $1.55M in Q2 2017. 105 funds tracked by Wall St. Rank hold CPRX as of Q4 2017.

  • Candriam SCA reported no remaining Catalyst Pharmaceutical position as of Q4 2017 after selling out during the quarter.
  • Candriam SCA sold 560,000 Catalyst Pharmaceutical shares in Q4 2017, an estimated $1.41M.
  • Candriam SCA first reported a position in Catalyst Pharmaceutical in Q1 2017 and held it in 3 quarters.
  • Candriam SCA's Catalyst Pharmaceutical position peaked at $1.55M in Q2 2017.
  • 105 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2017.

Based on Candriam SCA's 13F filing for Q4 2017, filed 7 Feb 2018.